{"id":8188,"date":"2025-10-29T16:10:38","date_gmt":"2025-10-29T16:10:38","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8188"},"modified":"2025-10-29T16:10:38","modified_gmt":"2025-10-29T16:10:38","slug":"purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/","title":{"rendered":"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Purple Biotech (PPBT), a clinical-stage biotechnology company focused on novel cancer immunotherapies, announced a major advancement in its antibody development program with the successful manufacturing of <strong>IM1240<\/strong>, its first <strong>tri-specific antibody<\/strong> from the company\u2019s <strong>CAPTN-3 platform<\/strong>. The achievement marks the establishment of a commercially viable yield and purity level\u2014an important step toward future clinical applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">IM1240 is designed to target <strong>5T4<\/strong>, a tumor-associated antigen, while simultaneously engaging the <strong>CD3<\/strong> receptor on T cells and blocking the <strong>NKG2A<\/strong> inhibitory receptor on NK and CD8\u207a T cells. This <strong>triple mechanism of action<\/strong> aims to trigger a strong and localized immune response against cancer cells while reducing the risk of systemic immune activation. An <strong>Investigational New Drug (IND) submission<\/strong> is planned for <strong>2026<\/strong>, paving the way for first-in-human trials.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CEO <strong>Gil Efron<\/strong> emphasized that developing a scalable and efficient process for producing tri-specific antibodies represents a major scientific and operational milestone. \u201cOur CAPTN-3 platform now demonstrates competitive yield and purity, positioning Purple Biotech at the forefront of next-generation immune oncology solutions,\u201d he stated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dr. Michael Schickler<\/strong>, Head of Clinical and Regulatory Affairs, highlighted the technical breakthrough, noting that the IM1240 antibody\u2019s <strong>protease-cleavable albumin-bound cap<\/strong> prevents systemic immune activation, focusing the immune response within the <strong>tumor microenvironment<\/strong>. This design is intended to enhance both safety and therapeutic durability.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The CAPTN-3 platform\u2019s ability to <strong>conditionally activate<\/strong> immune responses through tri-specific targeting positions Purple Biotech as an emerging leader in <strong>tumor-immune evasion<\/strong> research, combining innovation, scalability, and clinical readiness as it moves closer to first-in-human evaluation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/28\/orion-group-holdings-delivers-strong-q3-results-and-raises-2025-guidance\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026 Purple Biotech (PPBT), a clinical-stage biotechnology company focused on novel cancer immunotherapies, announced a major advancement in its antibody development program with the successful manufacturing of IM1240, its first tri-specific antibody from the company\u2019s CAPTN-3 platform. The achievement marks the establishment [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1127,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,358],"tags":[],"coauthors":[454],"class_list":["post-8188","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-micro-cap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240 - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240 - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026 Purple Biotech (PPBT), a clinical-stage biotechnology company focused on novel cancer immunotherapies, announced a major advancement in its antibody development program with the successful manufacturing of IM1240, its first tri-specific antibody from the company\u2019s CAPTN-3 platform. The achievement marks the establishment [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T16:10:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-edward-jenner-4033148-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1706\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240\",\"datePublished\":\"2025-10-29T16:10:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/\"},\"wordCount\":293,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-edward-jenner-4033148-scaled.jpg\",\"articleSection\":[\"Biotechnology\",\"Micro-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/\",\"name\":\"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240 - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-edward-jenner-4033148-scaled.jpg\",\"datePublished\":\"2025-10-29T16:10:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-edward-jenner-4033148-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-edward-jenner-4033148-scaled.jpg\",\"width\":2560,\"height\":1706,\"caption\":\"scientist\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/29\\\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240 - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/","og_locale":"en_US","og_type":"article","og_title":"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240 - Stoxpo","og_description":"Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026 Purple Biotech (PPBT), a clinical-stage biotechnology company focused on novel cancer immunotherapies, announced a major advancement in its antibody development program with the successful manufacturing of IM1240, its first tri-specific antibody from the company\u2019s CAPTN-3 platform. The achievement marks the establishment [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/","og_site_name":"Stoxpo","article_published_time":"2025-10-29T16:10:38+00:00","og_image":[{"width":2560,"height":1706,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-edward-jenner-4033148-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240","datePublished":"2025-10-29T16:10:38+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/"},"wordCount":293,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-edward-jenner-4033148-scaled.jpg","articleSection":["Biotechnology","Micro-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/","name":"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240 - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-edward-jenner-4033148-scaled.jpg","datePublished":"2025-10-29T16:10:38+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-edward-jenner-4033148-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-edward-jenner-4033148-scaled.jpg","width":2560,"height":1706,"caption":"scientist"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/29\/purple-biotech-reaches-key-manufacturing-milestone-for-groundbreaking-tri-specific-antibody-im1240\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8188"}],"version-history":[{"count":2,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8188\/revisions"}],"predecessor-version":[{"id":8190,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8188\/revisions\/8190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1127"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8188"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}